Lu AF35700

Drug Profile

Lu AF35700

Alternative Names: Lu-AF35700

Latest Information Update: 21 Jun 2017

Price : $50

At a glance

  • Originator Lundbeck A/S
  • Class Neuropsychotherapeutics
  • Mechanism of Action Dopamine D2 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Schizophrenia
  • Phase I Schizoaffective disorder

Most Recent Events

  • 14 May 2017 Lundbeck initiates enrolment in a phase I trial in Healthy volunteers in Germany (NCT03189615)
  • 28 Mar 2017 Phase-I clinical trials in Schizophrenia (In volunteers) in United Kingdom (PO) (NCT03103646)
  • 01 Sep 2016 Phase-I clinical trials in Schizoaffective disorder in USA (PO) (NCT02901587)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top